Abstract | BACKGROUND: METHODS: Sixteen patients with advanced or recurrent breast cancer were enrolled. Chemotherapy was given in a 28-day cycle, starting with MIT 10 mg/m2 intravenously on day 1, then oral 5'-DFUR 800 mg and MPA 800 mg daily. Two or more cycles were given. RESULTS: Fifteen patients were assessable for response and toxicity. Thirteen patients had been treated previously with an anthracycline containing regimen and 2 with CMF. There were 2 partial response patients (13.3%) and 1 complete response patient (6.7%). There were 11 patients showing no change (NC) (73.3%), one of whom was a minor responder and 7 with a long period of NC. There was only one with progressive disease patient. The overall response rate was 20.0%. Adverse events occurred in 5 patients (33.3%). Myelosuppression was the most common with 5 patients becoming leukopenic (33.3%). Nausea/ vomiting was the second most common side effect, affecting 2 patients (13.3%). CONCLUSION: Given its high efficacy and preservation of QOL, the combination of MIT, 5'-DFUR and MPA can be a 2nd or 3rd line therapy for advanced or recurrent breast cancer, especially for anthracycline-resistant cases.
|
Authors | K Sato, H Hiraide, S Tamakuma, T Tabei, M Maruyama, M Touma, H Okamura, F Matsumoto, S Akao, H Ishikawa, Y Yagi, H Mochizuki |
Journal | Breast cancer (Tokyo, Japan)
(Breast Cancer)
Vol. 8
Issue 1
Pg. 58-62
( 2001)
ISSN: 1340-6868 [Print] Japan |
PMID | 11180767
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antibiotics, Antineoplastic
- Floxuridine
- Mitoxantrone
- Medroxyprogesterone Acetate
- doxifluridine
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, metabolism, pathology)
- Drug Evaluation
- Drug Resistance, Neoplasm
- Female
- Floxuridine
(administration & dosage)
- Humans
- Medroxyprogesterone Acetate
(administration & dosage)
- Middle Aged
- Mitoxantrone
(administration & dosage)
- Neoplasm Recurrence, Local
(drug therapy)
- Salvage Therapy
- Time Factors
|